Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James F. Hopkins who wrote (762)	5/18/1997 3:32:00 AM
From: John Metcalf	of 6136

You want to buy below $50? Good luck! For comparison, Agouron is selling at about 40% of the market cap of Biochem Pharma, which has an aging AIDS drug with a promising application for hepatitis B. Compared to BCHXF, Agouron has a huge pipeline. For the record, Biochem is a buy at this level ($22), but will not increase as much as AGPH. When the number of switchers to Viracept is announced, in late July, this will be a $120 stock. When European approval is announced, this will be a $120 stock. If Roche buys the company, or a substantial part of it, this will be a $140 stock. The time has passed to look for bargains here.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next